Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...

Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients whose prostate cancer had returned, a large international clinical trial has ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in hepatocellular carcinoma patients. Median progression-free survival was 8.3 months with ...

Breakthrough yield and device performance at high volume show team can scale company's large-format advanced packaging for customers' cutting-edge applications SINGAPORE, Oct. 15, 2025 /PRNewswire/ -- ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...

A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...

Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom advance, according to findings published Oct. 7 in the journal Nature Medicine ...

Learn how to build a LEGO puzzle box using standard bricks. This tutorial explains each step of the building process including hidden mechanisms and lock designs made only from LEGO parts. Ideal for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...